MitoQ is a redesigned antioxidant that collects inside the cell's energy-producing compartments. Human trials repeatedly show better artery widening, but mainly where vessel function is already impaired, fading to nothing in regular exercisers. Endurance, physical function and neurological outcomes showed no gain. Lifespan claims rest on animals. Side effects are mild; years of continuous use are untested. (Full Review)

Protocol

Standard chronic dose

20 mg once daily

Mitoquinol mesylate, the dose used in the chronic vascular trials. Retail capsules contain 5 mg each.

Best time of day

Morning, 30 min before food

The empty-stomach requirement makes morning practical and keeps dosing distant from evening training.

Single versus split dosing

Single daily dose

All trials used a single daily dose; mitochondrial retention outlasts plasma exposure, so splitting offers no theoretical advantage.

Time to effect

Artery widening

6 weeks

Improvements were measured at six weeks of daily dosing, and at four weeks in kidney disease.

Walking capacity

1–2 hours

Acute vascular and walking effects appeared within one to two hours of an 80 mg dose.

Arterial stiffness

6 weeks

Six weeks lowered pulse wave velocity, but only in the subgroup that started stiff.

Benefits

High: Vascular endothelial function

Medium: Arterial stiffness; walking capacity in peripheral artery disease

Low: Exercise performance and physical function; liver enzyme reduction in chronic hepatitis C; blood pressure; reduced coronavirus infection after exposure

Speculative: Reduced circulating oxidised low-density lipoprotein; reduced exercise-induced oxidative and mitochondrial DNA damage; lifespan and neuroprotection in animal models; skin ageing and photodamage protection

Contraindications

Pregnancy or breastfeeding

Anyone under 18

Advanced chronic kidney disease (filtration below 30 mL/min/1.73 m², stages 4–5) or dialysis

Active cytotoxic chemotherapy or radiotherapy

Warfarin with unstable INR (outside 2.0–3.0 in the preceding three months)

Known hypersensitivity to quinone or triphenylphosphonium compounds

Key Interactions

Warfarin and other vitamin K antagonists (blood thinners)

Antihypertensives (amlodipine, lisinopril, losartan)

Antidiabetic agents (metformin, insulin, gliclazide)

Antacids and proton pump inhibitors (omeprazole, esomeprazole, calcium carbonate)

Non-targeted antioxidant supplements (vitamin C, vitamin E, N-acetylcysteine)

Nitrate-rich supplements (beetroot juice, L-Citrulline)

Coenzyme Q10 and ubiquinol supplements

Other mitochondria-directed supplements (urolithin A, pyrroloquinoline quinone, nicotinamide riboside)

Risk & Side Effects

Medium: Gastrointestinal reflux and nausea; headache

Low: Blunted acute aerobic capacity; no measurable vascular benefit in regularly exercising adults

Speculative: Renal mitochondrial injury; pro-oxidant redox cycling at high intracellular concentrations; unpredictable modulation of cancer therapy

Monitoring

Marker	Target	Why
Flow-mediated dilation	Above 7%	The primary documented endpoint
Carotid-femoral pulse wave velocity	Below 7.6 m/s	Large-artery stiffness
Blood pressure (home, seated)	Below 120/80 mmHg	Cheap proxy for vascular effect
Oxidised low-density lipoprotein	No established target; track the change from the individual's own baseline, aiming for a fall	The marker that moved in the vascular trial
High-sensitivity C-reactive protein	Below 1.0 mg/L	Systemic inflammation context
Alanine aminotransferase	10–26 U/L in men, 7–20 U/L in women	Liver injury, the one enzyme MitoQ moved
Estimated glomerular filtration rate with urine albumin-to-creatinine ratio	Above 90 mL/min/1.73 m² and below 10 mg/g	Safety floor for the unresolved kidney signal

Cadence: Home blood pressure weekly for the first month, then monthly. Blood panel and kidney measures at three months, then every six to twelve months while use continues. Vascular imaging, where done at baseline, repeated at three months.

Qualitative Assessment

Distance or duration walked before leg discomfort begins, if peripheral artery disease is present
Perceived recovery between hard training sessions
Daytime energy stability, recorded on a simple daily one-to-five scale
Cognitive clarity and sustained attention during demanding work
Sleep quality and time to fall asleep, to detect any unexpected disturbance
Reflux, nausea or headache frequency, which are the events most likely to end use

MitoQ for Health & Longevity

Protocol

Benefits

Risk & Side Effects

Monitoring

Qualitative Assessment